Reports Q4 revenue $140.6M, consensus $135.8M. “We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte’s (VCYT) chief executive officer. “We are achieving this growth while maintaining best-in-class profitability, with more than $50 million of cash generated from operations in the quarter. Looking ahead, 2026 will be an exciting year as we launch Prosigna as an LDT and TrueMRD, expanding our reach to more patients across the continuum of care while also continuing to invest in clinical evidence that reinforces the value and utility of our portfolio.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- VCYT Earnings this Week: How Will it Perform?
- Cathie Wood Buys the Dip in Joby Aviation (JOBY), Sells Teradyne (TER) Near Highs
- Cathie Wood Invests Over $3M Into Crypto Stock, Trims Stakes in Kratos Defense and TWST
- Veracyte: Strong Fundamentals and Margin Profile Offset by Execution Risks and Limited Valuation Upside, Justifying Hold Rating
- Veracyte: Strong Near-Term Performance but Execution and Valuation Risks Justify Sell Rating